G1 Therapeutics initiated at BTIG

G1 Therapeutics assumed with a Buy at BTIG. BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company’s “unique” position of potentially developing two “best in class” CDK4/6 inhibitors – trilaciclib and lerociclib. The analyst notes that trilaciclib’s positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, “significant upside” in the stock price remains thanks to the “large market opportunity” of both programs that he estimates to be around $2B by 2025
https://thefly.com/landingPageNews.php?id=2787719